表紙
市場調查報告書

全球抗逆轉錄病毒藥市場:成長,趨勢,預測

Anti-retroviral Drugs Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 391438
出版日期 內容資訊 英文 120 Pages
商品交期: 2-3個工作天內
價格
Back to Top
全球抗逆轉錄病毒藥市場:成長,趨勢,預測 Anti-retroviral Drugs Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年02月01日內容資訊: 英文 120 Pages
簡介

本報告提供全球抗逆轉錄病毒藥市場相關調查,提供市場趨勢與今後的成長預測,彙整各產品,各地區趨勢,及打入市場的主要企業簡介等資訊。

第1章 簡介

第2章 調查方法

第3章 摘要整理

第4章 主要推論

第5章 市場趨勢

  • 推動市場的要素
  • 阻礙市場的要素
  • 市場機會
  • 課題
  • 波特五力分析

第6章 市場區隔

  • 抗逆轉錄病毒
    • 蛋白分解酵素抑制劑
    • 非核苷酸逆轉錄抑制劑
    • 核苷酸類比及核苷酸逆轉錄抑制劑
    • Integrase抑制劑
    • 其他

第7章 各地區佔有率及預測

  • 北美
  • 歐洲
  • 亞太地區
  • 中東·非洲
  • 南美

第8章 競爭環境

  • 新產品上市
  • 合併·收購
  • 協定,聯合,聯盟

第9章 企業簡介

第10章 投資的機會相關分析師預測

第11章 市場未來發展預測

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 46540

Antiretroviral are the drugs that treat HIV. Factors contributing to the growth of the market includes rising burden of HIV, increasing investment in R&D and increase in availability of novel drugs with better efficacy. According to the U.S. Department of Health & Human Services, there were approximately 37.9 million people worldwide that were living with HIV/AIDS. An estimated 1.7 million individuals worldwide became newly infected with HIV in 2018. Anti-retrovirals (ARVs) are the foundation of HIV/AIDS management, as currently there is no cure or vaccine available for HIV. In individuals with a non-resistant strain of HIV, the antiretroviral treatment can suppress the replication of HIV in about 80% of cases. This huge patient pool shows that the market for anti-retroviral drugs is expected to grow in the forecast period.

Key Market Trends

Multi-class Combination Products is Expected to Register a Significant Growth in the Forecast Years

Based on drug class, it is segmented into Integrase Inhibitors, Protease Inhibitors, Multi-class Combination Products, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Others. The key factor contributing to the growth of the Multi-class Combination Products is the rising burden of HIV and new drug approval. According to WHO, around 770,000 people died from HIV in 2018. Many companies are focusing on developing breakthrough products for the treatment of antiretroviral drugs in order to maintain their competitive advantage and penetrate new regional markets. Additionally, the increase in funding for companies involved in the research related to anti-retroviral drugs is expected to boost the studied market.

North America holds the Largest Share in the Anti-retroviral Drugs Market

The Anti-retroviral Drugs market holds the largest share in the North America region. According to the U.S. Department of Health & Human Services, it is estimated that there are over 56,000 new cases of HIV in the United States each year and about 20 in 100 infected Americans do not know they have the virus. The growth is attributed to a high ART coverage rate and rising emphasis on prescribed branded drugs. In addition, the National Institutes of Health (NIH), United States, represents the largest public investment in HIV/AIDS research in the world, which is expected to fuel the market growth.

Competitive Landscape

The present demand of companies in the anti-retroviral segment is improving upon its research and development capabilities via collaboration, merger, and acquisition, as well as exploring new geographic regions. The global players in the anti-retroviral drugs market are - AbbVie Inc., Boehringer Ingelheim, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Gilead Sciences, Merck & Co, Inc., Mylan N.V., and ViiV Healthcare.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Burden of HIV
    • 4.2.2 Increasing Investment in R&D
    • 4.2.3 Increase in Availability of Novel Drugs with Better Efficacy
  • 4.3 Market Restraints
    • 4.3.1 Side Effects of Drugs
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug Class
    • 5.1.1 Protease Inhibitors
    • 5.1.2 Integrase Inhibitors
    • 5.1.3 Multi-class Combination Products
    • 5.1.4 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • 5.1.5 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • 5.1.6 Others
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle-East and Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle-East and Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AbbVie Inc.
    • 6.1.2 Boehringer Ingelheim International GmbH
    • 6.1.3 Bristol-Myers Squibb Company
    • 6.1.4 F. Hoffmann-La Roche Ltd
    • 6.1.5 Gilead Sciences, Inc.
    • 6.1.6 Merck & Co, Inc.
    • 6.1.7 Mylan N.V.
    • 6.1.8 ViiV Healthcare

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top